A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study
- Yusuke Chihara
- , Takayuki Takeda
- , Yasuhiro Goto
- , Yoichi Nakamura
- , Yuko Tsuchiya-Kawano
- , Akira Nakao
- , Keisuke Onoi
- , Makoto Hibino
- , Minoru Fukuda
- , Ryoichi Honda
- , Takahiro Yamada
- , Ryusuke Taniguchi
- , Sinjiro Sakamoto
- , Koji Date
- , Seiji Nagashima
- , Shigeru Tanzawa
- , Koichi Minato
- , Koichi Nakatani
- , Miiru Izumi
- , Takayuki Shimose
- Uji-Tokushukai Medical Center
- Japanese Red Cross Kyoto Daini Hospital
- Fujita Health University
- Tochigi Cancer Center
- Kitakyushu Municipal Medical Center
- Fukuoka University
- Kyoto Prefectural University of Medicine
- Shonan Fujisawa Tokushukai Hospital
- Nagasaki University
- Asahi General Hospital
- Matsushita Memorial Hospital
- Otsu City Hospital
- Hiroshima University
- Kyoto Chubu Medical Center
- National Hospital Organization Nagasaki Medical Center
- Gunma Prefectural Cancer Center
- National Hospital Organization Kyoto Medical Center
- National Hospital Organization Omuta National Hospital
- Clinical Research Support Center Kyushu
- Kyushu University
研究成果: ジャーナルへの寄稿 › 記事 › 査読
13
被引用数
(Scopus)